GlassScriptPhysician profile
Abdul M Malik
NPI 1952300584
$11,938.75
in general payments reported to CMS, 2019-2025
31 companies · $2,837 in 2025
The $2,837 reported for 2025 was more than what 84% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
See the full distribution for Sleep Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $269 · 2021: $246 · 2022: $4,172 · 2023: $1,447 · 2024: $2,452 · 2025: $2,837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,254 · Travel and Lodging: $1,397 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,254.31 |
| Travel and Lodging | $1,397.43 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $3,109.02 | 2023-2025 | Inspire |
| Brainsway USA INC | $2,321.77 | 2022-2025 | Deep Tms System |
| Noctrix Health, INC. | $1,278.15 | 2025 | Nidra |
| Zoll Respicardia, INC. | $1,166.26 | 2022-2024 | Remede System |
| Jazz Pharmaceuticals INC. | $629.83 | 2019-2025 | Xywav |
| Otsuka America Pharmaceutical, INC. | $534.36 | 2019-2023 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Harmony Biosciences LLC | $445.30 | 2022-2025 | Wakix |
| Neurocrine Biosciences, INC. | $376.27 | 2019-2023 | Ingrezza |
| Resmed Corp | $287.72 | 2019-2025 | |
| Itamar Medical INC | $270.79 | 2024-2025 | Watchpatone |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $210.02 | 2022-2023 | |
| Abbvie INC. | $196.83 | 2021-2024 | |
| Avadel Cns Pharmaceuticals, LLC | $187.23 | 2024-2025 | Lumryz |
| Takeda Pharmaceuticals U.S.A., INC. | $139.83 | 2019-2023 | Trintellix |
| Axsome Therapeutics, INC. | $125.48 | 2023-2024 | Sunosi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ensodata, INC. | $102.20 | 2025 | |
| Allergan, INC. | $93.62 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $75.20 | 2023 | Abilify Asimtufii |
| Alkermes, INC. | $71.44 | 2022-2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $60.99 | 2021-2023 | Spravato |
| Teva Pharmaceuticals USA, INC. | $50.53 | 2022-2023 | Austedo |
| Lundbeck LLC | $41.63 | 2021-2022 | |
| Corium, LLC | $35.09 | 2023 | Azstarys |
| Kerecis Limited | $27.35 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Indivior INC. | $18.56 | 2019 | |
| Teleflex LLC | $14.66 | 2025 | Guideliner |
| Idorsia Pharmaceuticals US INC | $14.49 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $14.06 | 2020 | |
| Glaxosmithkline, LLC. | $13.52 | 2024 | Ojjaara |
| Sunovion Pharmaceuticals INC. | $13.38 | 2020 | |
| Eisai INC. | $13.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.